JP2022530322A5 - - Google Patents

Info

Publication number
JP2022530322A5
JP2022530322A5 JP2021559917A JP2021559917A JP2022530322A5 JP 2022530322 A5 JP2022530322 A5 JP 2022530322A5 JP 2021559917 A JP2021559917 A JP 2021559917A JP 2021559917 A JP2021559917 A JP 2021559917A JP 2022530322 A5 JP2022530322 A5 JP 2022530322A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
alkyl
acceptable salt
solvate
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530322A (ja
JP7700045B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000288 external-priority patent/WO2020212755A1/en
Publication of JP2022530322A publication Critical patent/JP2022530322A/ja
Publication of JP2022530322A5 publication Critical patent/JP2022530322A5/ja
Application granted granted Critical
Publication of JP7700045B2 publication Critical patent/JP7700045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559917A 2019-04-18 2020-04-16 眼障害を処置するための化合物および方法 Active JP7700045B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962835963P 2019-04-18 2019-04-18
US62/835,963 2019-04-18
PCT/IB2020/000288 WO2020212755A1 (en) 2019-04-18 2020-04-16 Compounds and methods for the treatment of ocular disorders

Publications (3)

Publication Number Publication Date
JP2022530322A JP2022530322A (ja) 2022-06-29
JP2022530322A5 true JP2022530322A5 (cg-RX-API-DMAC10.html) 2024-03-26
JP7700045B2 JP7700045B2 (ja) 2025-06-30

Family

ID=72837744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559917A Active JP7700045B2 (ja) 2019-04-18 2020-04-16 眼障害を処置するための化合物および方法

Country Status (9)

Country Link
US (4) US10875845B2 (cg-RX-API-DMAC10.html)
EP (1) EP3955926A4 (cg-RX-API-DMAC10.html)
JP (1) JP7700045B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220003555A (cg-RX-API-DMAC10.html)
CN (1) CN114025759A (cg-RX-API-DMAC10.html)
AU (1) AU2020259996B2 (cg-RX-API-DMAC10.html)
CA (1) CA3137583A1 (cg-RX-API-DMAC10.html)
IL (1) IL287264A (cg-RX-API-DMAC10.html)
WO (1) WO2020212755A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212755A1 (en) * 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
CN116635032A (zh) * 2020-10-21 2023-08-22 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法
EP4232458A4 (en) * 2020-10-21 2024-10-02 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
US11459351B1 (en) 2021-04-05 2022-10-04 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
WO2023067387A2 (en) * 2021-10-20 2023-04-27 Azura Ophthalmics Ltd. Compounds and methods for the treatment of dermal and ocular disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US20040005641A1 (en) 2002-02-15 2004-01-08 Michael Burnet Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2004287875B2 (en) * 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
SI1881823T1 (sl) 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
DE102005062987A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP3632444A3 (en) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2877465A4 (en) * 2012-07-25 2016-05-11 Sarcode Bioscience Inc LFA-1 HEMMER AND POLYMORPH THEREOF
EP3827823A1 (en) * 2012-12-19 2021-06-02 Novartis AG Lfa-1 inhibitor formulations
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
CA3020713A1 (en) * 2016-04-19 2017-10-26 Azura Ophthalmics Ltd. Compositions for the treatment of hyperkeratosis disorders
US11420995B2 (en) 2017-03-03 2022-08-23 Synovo Gmbh Anti-infective and anti-inflammatory compounds
CA3057569A1 (en) 2017-03-29 2018-10-04 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
WO2019053607A1 (en) * 2017-09-18 2019-03-21 Glenmark Pharmaceuticals Limited PROCESS FOR PREPARING LIFITEGRAST
AU2020259997B2 (en) 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
WO2020212755A1 (en) 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
CA3196145A1 (en) 2020-10-21 2022-04-28 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
US11459351B1 (en) 2021-04-05 2022-10-04 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Similar Documents

Publication Publication Date Title
JP5524181B2 (ja) 治療剤としての置換ガンマラクタム
JP2022529315A5 (cg-RX-API-DMAC10.html)
JP2020521767A5 (cg-RX-API-DMAC10.html)
JP6270848B2 (ja) ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下
JP2012525437A5 (cg-RX-API-DMAC10.html)
JP2011507878A5 (cg-RX-API-DMAC10.html)
JP2011510965A (ja) 高眼圧症の治療のためのジフルオロビフェニルアミド誘導体
CA2679198A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2022509206A5 (cg-RX-API-DMAC10.html)
JP2023512823A5 (cg-RX-API-DMAC10.html)
US9150537B2 (en) Bicyclic compound and use thereof for medical purposes
KR20130029049A (ko) 아데노신 화합물 및 이의 용도
JP2016513707A (ja) 眼神経保護を与える方法
EP0777669A1 (en) 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol succinate as antiviral agent
RU2019111188A (ru) Кетоновые ингибиторы лизин-специфичного гингипаина
JP2011515406A (ja) 治療用の置換シクロペンタン類
JP2004506010A5 (cg-RX-API-DMAC10.html)
WO2005007161A1 (ja) ピペリジン誘導体を有効成分とする掻痒治療剤
JP2011518834A (ja) 治療剤としての置換ガンマラクタム
JP2011515409A (ja) 治療用化合物
JP5254007B2 (ja) 置換β−ラクタム及び医薬におけるその使用
DK3107906T3 (en) REDUCED CENTRAL CORNER MAP THICKNESS USING HYDROFILE ESTER PRODRUGS OF BETA-CHLORCYCLOPENTANE
JP2001515897A (ja) トロンボキサンリガンド
JP2024538954A (ja) 皮膚および眼の障害を処置するための化合物および方法
WO2021145355A1 (ja) 近視の治療、近視の予防および/または近視の進行抑制のための医薬組成物